Scientists Built a Gut Bacteria Blend That Reverses Colitis Two Ways at Once

If you've ever wondered why a probiotic didn't touch your gut inflammation, a new mouse study offers a clue: which bacteria you take may matter less than how those bacteria talk to your immune system. Researchers building next-generation bacterial therapies for inflammatory bowel disease (IBD, an umbrella term covering Crohn's disease and ulcerative colitis) found that a carefully designed blend of human gut bacteria could reverse colitis (inflammation of the colon) that was already established in mice, and it did so through two separate mechanisms working at the same time. The study, published in Cell Host & Microbe, points to a therapeutic strategy that goes well beyond the mechanisms earlier microbiome therapies leaned on.

Key takeaways

• Two defined bacterial blends made of human-derived Clostridia strains, a 17-strain mix and an 11-strain mix, reversed already-established colitis across two different mouse models.
• The bacteria worked two ways at once: directly suppressing harmful resident gut microbes, and switching on an anti-inflammatory immune pathway that does not depend on the mechanisms researchers previously assumed were doing the work.
• The second mechanism ran through tryptophan metabolites (breakdown products of an amino acid) that activate the aryl hydrocarbon receptor (AhR), a pathway increasingly linked to gut immune balance.
• This is an early-stage mouse study of an investigational bacterial drug. It has not been tested in humans, so it is not an available IBD treatment and nothing here should be read as diet or supplement advice.

Two Defined Clostridia Consortia Reversed Established Colitis

Researchers led by Akihiko Oka, with collaborators spanning the University of North Carolina at Chapel Hill, Shimane University in Japan, Keio University, RIKEN, and the pharmaceutical company Johnson & Johnson, tested two live biotherapeutic products (LBPs, lab-manufactured mixtures of live bacteria designed to work as drugs) built from human-derived Clostridia bacteria. One blend combined 17 distinct bacterial strains, the other 11, and both were designed to restore populations of beneficial gut bacteria that tend to be depleted in people with IBD. In the study, published in Cell Host & Microbe, both blends treated colitis that was already established, rather than only preventing it from developing, across two different mouse models of the disease.

Why This Matters for the Millions Living With IBD

IBD, which includes Crohn's disease and ulcerative colitis, affects an estimated 4.1 million adults in the United States, according to CDC survey data. Current first-line treatments for moderate to severe disease are biologic drugs that broadly dampen the immune system; they do not work for everyone and carry infection risk. Restoring specific bacteria that are missing from an inflamed gut has long been proposed as a gentler alternative, but bacterial therapies tested in people so far have shown inconsistent results, partly because it has not been clear which of the many things gut bacteria do is actually responsible for any benefit. This study is an attempt to pin that down before moving further toward the clinic, which matters directly to anyone managing Crohn's or ulcerative colitis and watching for new treatment options beyond biologics.

Gnotobiotic and Humanized Mouse Colitis Models

To test the two bacterial blends, the researchers used two different colitis models. The first was a chronic, T cell-mediated colitis induced using human gut microbiota transplanted into mice. The second was a gnotobiotic model (mice raised germ-free, then deliberately colonized with a known, controlled set of bacteria) built from combinations of IBD-relevant, human-derived pathobiont strains (pathobionts are bacteria that are normally harmless but can turn inflammatory under the wrong conditions). Using both models let the team check whether the treatment held up in more than one representation of human-like disease. They then applied metagenomic sequencing (reading the genetic material of the entire bacterial community) and metabolomic analysis (measuring the small molecules those bacteria actually produce) to work out how the treatment was having its effect, rather than simply confirming that it worked.

What the Dual Mechanism Means for Gut Health

The expected explanation was the one already established in the field: beneficial Clostridia produce short-chain fatty acids (SCFAs, small molecules made by bacteria fermenting fiber) that support IL-10-producing regulatory T cells, a type of immune cell that keeps inflammation in check. The new analysis found the two LBPs were doing something in addition to that. First, they directly suppressed resident pathobionts, including bacteria from the Enterobacteriaceae and Fusobacteria groups that are often overrepresented in an inflamed IBD gut. Second, and independent of the IL-10 pathway, the bacteria activated the host's aryl hydrocarbon receptor (AhR), an anti-inflammatory signaling pathway found on immune and gut-lining cells, through bacterial tryptophan metabolites, most notably indole-3-propionic acid (IPA), a molecule gut bacteria make by breaking down the amino acid tryptophan. AhR is already known to help regulate gut inflammation, but this study ties a defined, drug-like bacterial blend to switching it on through a route that does not require IL-10 at all. That is useful because it gives researchers a second lever to pull if the first one is blunted, as it often is in IBD.

Limitations: This Is Still a Mouse Study

The evidence here is investigational, not established. Every result described above comes from mouse models, and mouse colitis models are known to translate imperfectly to human IBD, which is a more heterogeneous disease. The published summary of the work does not report the exact magnitude of colitis reduction in each model, and the specific strain-by-strain contributions within the 17-strain and 11-strain blends were not detailed at the level available here. This is also a single study from one collaborating group, and it has not yet been independently replicated by outside labs. No human trial data exists yet for either blend.

What Comes Next for These Bacterial Therapies

This work builds on the same collaboration's earlier effort to rationally design multi-strain bacterial consortia for colitis, reported in Nature Communications in 2021, and the involvement of Johnson & Johnson suggests these blends, or close descendants of them, are candidates for further drug development rather than a one-off academic exercise. Turning a live biotherapeutic like this into an approved treatment typically requires years of manufacturing, safety, and Phase 1 through 3 human trials, so any clinical availability is likely years away, if the approach holds up at all.

Common Questions

What is a live biotherapeutic product (LBP)? An LBP is a drug made of live bacteria, manufactured under pharmaceutical-grade conditions and dosed like a medicine, rather than a loosely regulated probiotic supplement.

Is this bacterial blend available to patients now? No. It has only been tested in mice so far, and there is no approved product or ongoing consumer access.

Why does the aryl hydrocarbon receptor (AhR) matter for gut health? AhR is a receptor on immune and intestinal lining cells that, when activated by the right molecules, dials down inflammatory signaling; several studies have found AhR activity is reduced in the inflamed gut of people with IBD.

Should I try to increase tryptophan or IPA intake on my own? No. This study did not test dietary tryptophan or IPA supplementation in humans, and self-directed supplementation is not something this research supports; anyone managing IBD should discuss treatment changes with a gastroenterologist.

References

1. Akihiko Oka, Gerold Bongers, Yoshiyuki Mishima, et al. (2026). Defined human Clostridia consortia reverse colitis via dual effects of tryptophan metabolites on microbiota and immunity. Cell Host & Microbe. https://doi.org/10.1016/j.chom.2026.08.003
2. Inflammatory Bowel Disease Among Adults Age 18 and Older: United States, 2023-2024 (CDC/NCHS). cdc.gov. https://www.cdc.gov/nchs/data/hestat/hestat122.htm
3. Jun-Jie Hou, A-Huo Ma, Yue-Hua Qin (2023). Activation of the aryl hydrocarbon receptor in inflammatory bowel disease: insights from gut microbiota. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2023.1279172
4. Biological Effects of Indole-3-Propionic Acid, a Gut Microbiota-Derived Metabolite. NIH. https://pmc.ncbi.nlm.nih.gov/articles/PMC8835432/
5. Daniel van der Lelie, Akihiko Oka, Safiyh Taghavi, et al. (2021). Rationally designed bacterial consortia to treat chronic immune-mediated colitis and restore intestinal homeostasis. Nature Communications. https://doi.org/10.1038/s41467-021-23460-x